Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-Emptive CMV-Specific CTLs for CMV Reactivation Post-HSCT
NCT02210065Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2015
- Primary completion
- May 2019
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytomegalovirus-specific cytotoxic t lymphocytes in cytomegalovirus infection (CMV), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Number of Participants With Non-Relapse Mortality at 6 months and Success Rate of Cytotoxic T Cells at 28 days. Started Mar 2015; status: completed.
02
Drugs
cytomegalovirus-specific cytotoxic t lymphocytes
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02210065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210065.